Open Access

Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension

  • Authors:
    • Jia Liu
    • Jiamei Liu
    • Linying Shi
    • Fan Zhang
    • Liping Yu
    • Xinchun Yang
    • Jun Cai
  • View Affiliations

  • Published online on: January 23, 2018     https://doi.org/10.3892/ijmm.2018.3420
  • Pages: 1835-1844
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to explore microRNA-126 (miR-126) as a novel therapeutic target for primary hypertension. The lentiviral vector containing human immunodeficiency virus 1 (HIV‑1), the miR‑126 gene knockdown viral vector (lenti-miR-126-KD), and control lentiviral vector (lenti‑scramble‑miR) were constructed. Spontaneously hypertensive rats were randomly divided into 4 groups, which received a high dose of lenti‑miR‑126‑KD (1x108, n=5), low dose of lenti‑miR‑126‑KD (1x107, n=6), scramble‑miR (5x107, n=6), and PBS (n=6). Lentiviral vectors were injected into the tail vein. Data on the systolic blood pressure, diastolic pressure, mean arterial pressure, and heart rate were collected weekly. After 8 weeks of virus administration, the distribution of lentiviral vectors in different tissues was observed by fluorescence microscopy. Picric acid Sirius red and H&E staining were used to observe the target organ damage, and the ELISA kit was used to determine the serum nitric oxide (NO) content. The lentiviral vector was found to be constructed successfully. Eight weeks after the lentiviral vector injection, green fluorescent protein was observed in different tissues in each group. The blood pressure and heart rate were not significantly altered after lentiviral vector injection (P>0.05). No significant differences in the heart‑to‑body weight ratio among the four groups were observed (P=0.23). Picric acid Sirius red and H&E staining revealed that there was no significant difference in morphology among the four groups. No significant difference in the serum NO level among the four groups was noted (P=0.23). The miR‑126 gene knockdown lentiviral vector was constructed successfully. No significant antihypertensive effect was observed by the knockdown of miR‑126 for the treatment of primary hypertension. The target organs were not protected significantly after the treatment. The increased level of miR‑126 expression in hypertensive patients may be due to a compensatory mechanism.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 41 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu J, Liu J, Shi L, Zhang F, Yu L, Yang X and Cai J: Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension. Int J Mol Med 41: 1835-1844, 2018
APA
Liu, J., Liu, J., Shi, L., Zhang, F., Yu, L., Yang, X., & Cai, J. (2018). Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension. International Journal of Molecular Medicine, 41, 1835-1844. https://doi.org/10.3892/ijmm.2018.3420
MLA
Liu, J., Liu, J., Shi, L., Zhang, F., Yu, L., Yang, X., Cai, J."Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension". International Journal of Molecular Medicine 41.4 (2018): 1835-1844.
Chicago
Liu, J., Liu, J., Shi, L., Zhang, F., Yu, L., Yang, X., Cai, J."Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension". International Journal of Molecular Medicine 41, no. 4 (2018): 1835-1844. https://doi.org/10.3892/ijmm.2018.3420